Navigation Links
Gynecologic cancer expert helps pinpoint best treatment for fast-growing gestational tumors
Date:4/25/2011

DALLAS April 26, 2011 A clinical trial has sifted out the most effective single-drug chemotherapy regimen for quick-growing but highly curable cancers that arise from the placentas of pregnant women.

In the comparison trial for treating low-risk gestational trophoblastic neoplasia (GTN), researchers found that a biweekly dose of dactinomycin had a higher complete response rate than a weekly dose of methotrexate, the more commonly used drug. GTN is a group of rare tumors that involve abnormal growth of cells inside a woman's uterus.

"Both chemotherapy drugs are effective in treating this kind of neoplasia, but this trial proved that dactinomycin is the best first-line regimen," said Dr. David Scott Miller, who is the head of gynecologic oncology at UT Southwestern Medical Center and co-investigator on the study.

The trial, supported by grants from the National Cancer Institute to the Gynecologic Oncology Group, was published in the March issue of the Journal of Clinical Oncology.

Dr. Miller, professor of obstetrics and gynecology, chairs the uterine corpus committee of the Gynecologic Oncology Group. As group members, UT Southwestern specialists are able to offer patients access to national protocols supported by the institute.

Unlike cervical or endometrial cancers, which develop from cells of the uterus, trophoblastic neoplasia starts in the cells that would normally develop into the placenta during pregnancy. These tumors include hydatidiform moles, caused by over-production of the tissue that typically develops into the placenta, and choriocarcinoma, a quick-growing form of cancer in a woman's uterus.

There has been no consensus on which drug and regimen best treats GTN, and researchers found that such choices were highly institution-specific.

In this trial, researchers compared regimens of both cancer drugs in a sample of 216 women enrolled over an eight-year period. Adverse effects were minimal with either drug, but a biweekly dose of intravenous dactinomycin was superior to a weekly intramuscular injection of methotrexate in stopping the growth of cancerous cells in the uterus. Dactinomycin had a 70 percent complete response rate compared to 53 percent for methotrexate.

Study patients who received dactinomycin also required half the number of treatment cycles. Dactinomycin additionally was easy to administer and had low toxicity a strong consideration for young reproductive-age women.

"Minimizing toxicity is essential in low-risk GTN, because these women have a high-cure rate and usually hope to have subsequent pregnancies," Dr. Miller said. "These tumors are much more common in developing countries, where access to more complicated chemotherapy regimens is limited. The Gynecological Oncology Group has sought to develop simpler but effective regimens that would lend themselves to use in low-resource settings."

Researchers said further trials comparing the biweekly dactinomycin regimen with other methotrexate regimens are warranted.


'/>"/>

Contact: Robin Russell
robin.russell@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Most women facing gynecologic surgery dont worry about its effects on sex
2. Targeted agent selumetinib shows promise in biliary cancer
3. Public session of the Cancer Drug Development Roundtable at Ohio State
4. New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds
5. Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer
6. Acupuncture May Help Ease Hot Flashes Tied to Prostate Cancer Treatment
7. Smoking Could Raise Odds for Advanced Kidney Cancer
8. ACE Inhibitors Seem to Raise Risk of Breast Cancer Recurrence
9. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
10. Acupuncture relieves hot flashes from prostate cancer treatment
11. Worm studies shed light on human cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... BC (PRWEB) , ... March 29, 2017 , ... ... makeover services with or without a referral to new patients from Burnaby, BC. ... or other full mouth reconstruction services, can see the esteemed team at ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... March 29, 2017  BioSpecifics Technologies Corp. (NASDAQ: ... to develop collagenase based-therapies with a first in ... as XIAFLEX ®  in the U.S. and Xiapex ... a corporate overview at the upcoming 16 th ... 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology: